Initial data from a phase I trial of Glaxosmithkline (GSK) plc's Ebola virus vaccine were published on Wednesday, showing the product is safe and immunogenic. The results were released as the first shipment of the vaccine reached one of the countries hit by the epidemic, with 300 vials arriving in Liberia, West Africa.
In the phase I trial at Oxford University's Jenner Institute, 60 volunteers received a single dose of the chimpanzee adenovirus3 vector (ChAd3-EBOV) vaccine at three dose levels. There were no safety concerns and the monovalent vaccine was immunogenic at the doses tested.
"We are very pleased with the results, which are exactly as we would have predicted; there was very good safety," said Adrian Hill, who led the study published online in The New England Journal of Medicine on Jan. 28, 2015.
"Three other trials have completed but not published, and to date more than 200 people have received the vaccine," Hill told